– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2 Seabreeze STAT studies mid-2026 – – $20.2 million private placement financing closed on March 31, 2026 – SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three months ended March 31, 2026, and provided a business update. “We have had a strong start to the year as we continue to build upon the body of preclinical and clinical evidence supporting the potential of rademikibart...

Q1 2026 in the BANK of Greenland With a profit before tax of DKK 36.3 million for Q1, the BANK of Greenland made a favourable start to 2026. As expected, the result is affected by the declining level of interest rates during 2025, and is also below the profit of DKK 39.1 million for the same period of 2025. Core earnings amounted to DKK 37 million, compared to DKK 45 million for the previous year. Lending has decreased by DKK 23 million since the end of 2025, amounting to DKK 4,899 million at the end of March 2026. Guarantees increased by DKK 74 million, from DKK 1,275 million at the end of 2025 to DKK 1,349 million at the end of March 2026. It was expected that the declining level of interest rates would increase the Bank’s customers’ appetite for investment, thereby a moderate growth in the Bank’s lending in 2026. A positive effect...

Q1’26 Revenue $72.8 million Q1’26 Op Inc ($12.9) million loss due to revenue miss and staffing for Q3’26 growth Convertible note offering reduced debt by $40 million Bookings increased to a record 4,446 jobs, up from 1,197 in Q1’25 due to acquisitions 2025 10K statement filed on time; difficult 10K audit We plan to file the Q1’25-Q3’25 10Q restatements on timeOREM, Utah, May 12, 2026 (GLOBE NEWSWIRE) — SunPower Inc. (herein “SunPower,” the “Company,” or Nasdaq: “SPWR”), a solar technology, services, and installation company, will present its Q1’26 results via webcast today, Tuesday, May 12, at 1:00pm ET. Register for the webcast here or by visiting our Events page: https://investors.sunpower.com/news-events/events. Fellow Shareholders:The preliminary, unaudited Q1’26 report is shown below, compared to the Q4’25 results from...

Higher Gross Margins Reflect Strategic Shift to Recurring Merchandising RevenueCompany Reiterates Full-Year Financial Guidance CHARLOTTE, N.C., May 12, 2026 (GLOBE NEWSWIRE) — SPAR Group, Inc. (NASDAQ: SGRP) (“SGRP”, and together with its subsidiaries, “SPAR,” “SPAR Group” or the “Company”), an innovative services company offering comprehensive merchandising and marketing solutions for retailers and brands throughout the United States and Canada, today reported financial results for the period ended March 31, 2026. William Linnane, President and Chief Executive Officer of SPAR Group, commented, “I am pleased to report that SPAR returned to positive EBITDA and delivered substantially higher gross margins than the prior year.   Though revenue was down year-on-year, driven by a decline in our US Remodel business, we were pleased to...

Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701 Announced presentation of updated CRB-701 data in HNSCC and cervical cancer at ASCO 2026 Completed enrollment in 16-week study CANYON-1 study (n=240) of CRB-913 for the treatment of obesity with topline data on track to report this summerNORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 first quarter ended March 31, 2026.  “We’ve continued to build strong momentum with CRB-701 and CRB-913, setting the...

MINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter and Recent Highlights:Net sales were $2.4 million, a 26% increase compared to the prior-year period Gross margin improved to 70.1%, reflecting improved pricing, product mix, and the transition to contract manufacturing Completed the acquisition of Rendiatech, adding automated kidney-function monitoring capabilities to the Company’s product development portfolio Appointed Carisa Schultz as Chief Financial Officer and Dr. Stuart L. Goldstein as Director of Clinical Strategy Appointed Martin J. Emerson and reappointed David A. McDonald to the Board of Directors Expanded...

Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) — Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2026. “In March, we introduced Transform and Transcend to our investor community, the strategic initiative that we began at the end of 2025,” commented Kevin Cureton, President and Chief Executive Officer. “Our first quarter results reflect our disciplined execution on this initiative, particularly on our first and foundational pillar, operational excellence. Combined with steady early progress in our efforts to further leverage our intellectual...

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer New England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumors Rezatapopt New Drug Application submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 Cash, cash equivalents, and marketable securities of $93.5 million as of March 31, 2026 providing expected cash runway to end of second quarter of 2027PRINCETON, N.J., May 12, 2026 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the first...

Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials remain on track for 2027 year-end initiation $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the first quarter ended March 31, 2026 and provided business updates. “I am happy to report that new batches...

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026 Consistent, convergent improvements demonstrated in EMP-01 Phase 2a trial across independent clinician-rated and patient-reported outcomes in Social Anxiety Disorder Cash and cash equivalents expected to fund operations through anticipated BPL-003 Phase 3 topline readouts, with runway into 2029NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) — AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today reported financial results for the first quarter ended March 31, 2026, and provided a business update across...